Medical/Pharmaceuticals

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference("JPMHC")2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...

2024-01-11 17:55 1478

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference("JPMHC")2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...

2024-01-11 16:32 1643

SyntheticGestalt and Enamine to Collaborate on the Creation of AI-Based Model to Facilitate Drug Discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates. This model will utilize 38 billion compounds from Enamine REAL database as a dataset for pre-training. TOKYO and KYIV, Ukraine, Jan. 11, 2024 /PRNewswire/ -- SyntheticGestalt, a research and ...

2024-01-11 16:00 1309

Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a commercial stage global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Dr.Dajun Yang, the company's ...

2024-01-11 11:53 4344

Robooter Showcases Innovative Power Wheelchair X40 at CES 2024

LAS VEGAS, Jan. 10, 2024 /PRNewswire/ -- Robooter, a leading autonomous mobility device manufacturer renowned for its robotic technology supporting the elderly and disabled, is proud to present the innovative power wheelchair X40 and offer a new space and mobility solution through its partners at...

2024-01-11 01:00 1085

A New Study Shows GlycoMark is a Novel Biomarker of SGLT-2i Adherence

RALEIGH, N.C., Jan. 10, 2024 /PRNewswire/ -- A new study, "1,5-Anhydroglucitol: A Novel Biomarker of Adherence in Sodium -Glucose Cotransporter 2 Inhibitors," was published online onDecember 13, 2023, in Diabetes Care, a journal from the American Diabetes Association. The study was conducted b...

2024-01-10 20:00 1221

More accurate tumour treatment thanks to superconductive ASG Superconductors technology

GENOA, Italy and DRESDEN, Germany, Jan. 10, 2024 /PRNewswire/ -- ASG Superconductors' (ASG) MgB2 superconducting technology - already in use for energy and medical applications such as the world's only truly open MROpenEVO magnetic resonance imaging (MRI) system - is at the heart of the worldwide...

2024-01-10 18:49 2060

New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

HONG KONG, Jan. 10, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development  of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare...

2024-01-10 16:50 1245

Novogene Bolsters Global Presence with Expanded PacBio Revio Fleet, Advancing Long-Read Sequencing Applications

SINGAPORE, Jan. 10, 2024 /PRNewswire/ -- Novogene further expands its long-read sequencing capacity with the acquisition of six additional PacBio Revio sequencers, augmenting its fleet of multi-platforms sequencing technology. This strategic investment underline Novogene's commitment to enhancing...

2024-01-10 10:30 2045

LOTTE BIOLOGICS Announces Songdo Bio Plant Development Plan at JPM Healthcare Conference 2024

* Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year * Unveils company's bio plant development plan in Songdo to meet clients' needs SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- LOTTE BIOLOGICS (CEO Richard Lee) ...

2024-01-10 08:55 1205

Health Recovery Solutions (HRS) Applauded by Frost & Sullivan for Transforming Remote Care Delivery with Its Clinically Enabled, Patient-centric RPM Solutions

HRS's RPM solutions enhance patient outcomes and satisfaction, optimize hospital bed utilization, improve quality, reduce costs, and curb readmissions across diverse healthcare settings. SAN ANTONIO, Jan. 9, 2024 /PRNewswire/ -- Frost & Sullivan researched the remote patient monitoring (RPM) ind...

2024-01-09 23:00 1197

Last Chance for Animals, Animal Liberation Wave Applaud Historic Victory for Compassion as South Korea Bans Dog Meat

SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- In a monumental step towards a more compassionate and humane society, Last Chance for Animals (LCA) and Animal Liberation Wave (ALW) celebrate the recent decision bySouth Korea to ban dog meat. This historic move underscores a profound shift toward...

2024-01-09 22:15 967

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing

PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing...

2024-01-09 22:00 1097

Toratani Co., Ltd. Unveils Groundbreaking "Virtuous Circulation Pillow and Mattress" with Patented Technology for Enhanced Deep Breathing Experience

New sleeping solutions that facilitate deeper breathing, improve sleep quality, and bring health benefits TOKYO, Jan. 9, 2024 /PRNewswire/ -- Toratani Co., Ltd. (Kahoku City, Ishikawa Prefecture,Japan) has announced the launch of their innovative Toratani Virtuous Circulation Mattress and Pillow...

2024-01-09 21:00 1064

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

Results published by the DETECT study group indicate the relevance of assessing biomarker expression in Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based CELLSEARCH® platform to optimize treatment strategy and outcome in patients at an advanced stage of their disease....

2024-01-09 18:55 1078

TOKIWA PHYTOCHEMICAL CO., LTD. Announces Latest Clinical Study of VENETRON (R) on Menstrual Well-being

SAKURA, Japan, Jan. 9, 2024 /PRNewswire/ -- TOKIWA PHYTOCHEMICAL CO., LTD. (hereinafter "Tokiwa"),Japan, has announced the publication of the latest research on VENETRON (R), extracted from rafuma leaves. The study, titled "Effect of Apocynum venetum Leaf Extract (VENETRON (R)) on Unidentified C...

2024-01-09 15:00 1225

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code :688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...

2024-01-09 12:25 1277

Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021)

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib(ABSK021) has been granted orphan drug designation(ODD) by the European Medicines Agency (EMA) for the treatm...

2024-01-09 08:30 1079

Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

ROCKVILLE, Md. and SUZHOU, China, Jan. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-01-09 08:00 3309

GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform

South Korea's first CAR-NK cell therapy cleared for human trials in Australia and domestically; Cancer Moonshot participant GC Cell partnering with medical AI leader Lunit to collaborate on AB-201 clinical development YONGIN, South Korea and SYDNEY, Jan. 9, 2024 /PRNewswire/ -- GC Cell

2024-01-09 00:00 1379
1 ... 33343536373839 ... 577